Maravai LifeSciences (MRVI) Stock Forecast, Price Target & Predictions
MRVI Stock Forecast
Maravai LifeSciences stock forecast is as follows: an average price target of $19.00 (represents a 253.82% upside from MRVI’s last price of $5.37) and a rating consensus of 'Buy', based on 7 wall street analysts offering a 1-year stock forecast.
MRVI Price Target
The average price target for Maravai LifeSciences (MRVI) is $19.00 based on 1-year price targets from 7 Wall Street analysts in the past 3 months, with a price target range of $25.00 to $10.00. This represents a potential 253.82% upside from MRVI's last price of $5.37.
MRVI Analyst Ratings
According to 7 Wall Street analysts, Maravai LifeSciences's rating consensus is 'Buy'. The analyst rating breakdown for MRVI stock is 0 'Strong Buy' (0.00%), 5 'Buy' (71.43%), 2 'Hold' (28.57%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Maravai LifeSciences Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| May 09, 2024 | Catherine Schulte | Robert W. Baird | $10.00 | $8.87 | 12.74% | 86.22% |
| Dec 14, 2022 | Deutsche Bank | $25.00 | $15.03 | 66.31% | 365.55% | |
| Dec 07, 2022 | RBC Capital | $22.00 | $12.50 | 76.00% | 309.68% |
The latest Maravai LifeSciences stock forecast, released on May 09, 2024 by Catherine Schulte from Robert W. Baird, set a price target of $10.00, which represents a 12.74% increase from the stock price at the time of the forecast ($8.87), and a 86.22% increase from MRVI last price ($5.37).
Maravai LifeSciences Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 1 |
| Avg Price Target | - | - | $10.00 |
| Last Closing Price | $5.37 | $5.37 | $5.37 |
| Upside/Downside | -100.00% | -100.00% | 86.22% |
In the current month, the average price target of Maravai LifeSciences stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Maravai LifeSciences's last price of $5.37. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Oct 08, 2024 | UBS | Underperform | Underperform | Hold |
| Oct 08, 2024 | Wells Fargo | Equal-Weight | Equal-Weight | Hold |
| Aug 27, 2024 | Wells Fargo | Overweight | Initialise | |
| Aug 13, 2024 | Morgan Stanley | Overweight | Equal-Weight | Downgrade |
| Aug 08, 2024 | UBS | Neutral | Neutral | Hold |
| Jun 03, 2024 | Jefferies | Buy | Buy | Hold |
| May 29, 2024 | RBC Capital | Outperform | Outperform | Hold |
| Feb 23, 2024 | William Blair | Outperform | Outperform | Hold |
| Dec 12, 2023 | Bank of America Securities | Buy | Upgrade | |
| Jan 05, 2023 | UBS | Neutral | Downgrade | |
| Dec 14, 2022 | Deutsche Bank | Buy | Initialise | |
| Dec 07, 2022 | RBC Capital | Outperform | Initialise | |
| Feb 25, 2022 | Morgan Stanley | Overweight | Overweight | Hold |
Maravai LifeSciences's last stock rating was published by UBS on Oct 08, 2024. The company gave MRVI a "Underperform" rating, the same as its previous rate.
Maravai LifeSciences Financial Forecast
Maravai LifeSciences Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | $66.86M | $68.91M | $79.03M | $204.71M | $191.26M | $242.73M | $244.29M | $228.44M | $204.81M | $217.78M | $148.21M | $98.35M |
| Avg Forecast | $70.01M | $68.33M | $62.89M | $57.48M | $68.58M | $67.87M | $67.33M | $64.79M | $56.67M | $67.55M | $71.92M | $60.54M | $64.37M | $75.47M | $71.10M | $80.00M | $204.93M | $195.11M | $233.22M | $232.29M | $208.09M | $201.50M | $194.81M | $138.49M | $89.60M |
| High Forecast | $75.72M | $73.90M | $68.02M | $62.17M | $74.17M | $73.41M | $72.82M | $69.30M | $59.61M | $67.62M | $72.06M | $60.54M | $67.04M | $79.55M | $76.90M | $86.52M | $221.64M | $195.11M | $233.22M | $232.29M | $208.09M | $201.50M | $194.81M | $138.49M | $89.60M |
| Low Forecast | $60.81M | $59.35M | $54.62M | $49.92M | $59.56M | $58.95M | $58.48M | $55.73M | $52.31M | $67.48M | $71.78M | $60.54M | $59.27M | $72.06M | $61.75M | $69.48M | $177.99M | $195.11M | $233.22M | $232.29M | $208.09M | $201.50M | $194.81M | $138.49M | $89.60M |
| # Analysts | 3 | 3 | 4 | 5 | 4 | 5 | 2 | 7 | 9 | 4 | 3 | 3 | 6 | 10 | 9 | 9 | 8 | 8 | 8 | 8 | 9 | 9 | 9 | 9 | 9 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.89% | 0.97% | 0.99% | 1.00% | 0.98% | 1.04% | 1.05% | 1.10% | 1.02% | 1.12% | 1.07% | 1.10% |
Maravai LifeSciences's average Quarter revenue forecast for Dec 23 based on 6 analysts is $64.37M, with a low forecast of $59.27M, and a high forecast of $67.04M. MRVI's average Quarter revenue forecast represents a -3.73% decrease compared to the company's last Quarter revenue of $66.86M (Sep 23).
Maravai LifeSciences EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 4 | 5 | 4 | 5 | 2 | 7 | 9 | 4 | 3 | 3 | 6 | 10 | 9 | 9 | 8 | 8 | 8 | 8 | 9 | 9 | 9 | 9 | 9 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | $-5.53M | $-8.76M | $8.75M | $112.50M | $116.90M | $171.63M | $174.75M | $83.87M | $88.74M | $76.31M | $52.62M | $28.23M |
| Avg Forecast | $45.47M | $44.37M | $40.84M | $37.33M | $44.54M | $44.08M | $43.73M | $42.07M | $36.80M | $43.87M | $46.71M | $39.32M | $41.81M | $49.01M | $46.17M | $51.95M | $75.27M | $83.74M | $100.10M | $74.87M | $89.31M | $86.49M | $83.61M | $40.09M | $38.46M |
| High Forecast | $49.18M | $47.99M | $44.17M | $40.37M | $48.17M | $47.67M | $47.29M | $45.01M | $38.71M | $43.92M | $46.80M | $39.32M | $43.54M | $51.66M | $49.94M | $56.19M | $90.32M | $83.74M | $100.10M | $89.84M | $89.31M | $86.49M | $83.61M | $48.11M | $38.46M |
| Low Forecast | $39.49M | $38.54M | $35.47M | $32.42M | $38.68M | $38.28M | $37.98M | $36.19M | $33.97M | $43.83M | $46.61M | $39.32M | $38.49M | $46.80M | $40.10M | $45.12M | $60.21M | $83.74M | $100.10M | $59.90M | $89.31M | $86.49M | $83.61M | $32.07M | $38.46M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | -0.11% | -0.19% | 0.17% | 1.49% | 1.40% | 1.71% | 2.33% | 0.94% | 1.03% | 0.91% | 1.31% | 0.73% |
9 analysts predict MRVI's average Quarter EBITDA for Jun 23 to be $46.17M, with a high of $49.94M and a low of $40.10M. This is 427.91% upper than Maravai LifeSciences's previous annual EBITDA (Mar 23) of $8.75M.
Maravai LifeSciences Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 4 | 5 | 4 | 5 | 2 | 7 | 9 | 4 | 3 | 3 | 6 | 10 | 9 | 9 | 8 | 8 | 8 | 8 | 9 | 9 | 9 | 9 | 9 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | - | $-6.46M | $-6.54M | $-1.35M | $87.43M | $99.65M | $156.72M | $146.86M | $127.11M | $54.27M | $49.08M | $23.25M | $13.13M |
| Avg Forecast | $-1.54M | $-2.13M | $-3.67M | $-5.29M | $-1.43M | $-2.00M | $-2.33M | $-3.19M | $-5.81M | $-1.18M | $142.83K | $62.52M | $-1.63M | $785.91K | $1.80M | $56.83M | $50.10M | $44.78M | $61.68M | $51.67M | $52.26M | $47.78M | $42.89M | $17.71M | $14.47M |
| High Forecast | $-1.27M | $-1.76M | $-3.04M | $-4.39M | $-1.19M | $-1.66M | $-1.93M | $-2.64M | $-2.90M | $-981.52K | $157.98K | $75.02M | $-1.35M | $1.57M | $1.99M | $68.20M | $60.12M | $44.78M | $61.68M | $62.00M | $52.26M | $47.78M | $42.89M | $21.25M | $14.47M |
| Low Forecast | $-1.70M | $-2.35M | $-4.06M | $-5.85M | $-1.58M | $-2.21M | $-2.58M | $-3.52M | $-7.26M | $-1.31M | $118.42K | $50.01M | $-1.80M | $-785.91K | $1.49M | $45.47M | $40.08M | $44.78M | $61.68M | $41.33M | $52.26M | $47.78M | $42.89M | $14.17M | $14.47M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | -8.22% | -3.63% | -0.02% | 1.75% | 2.23% | 2.54% | 2.84% | 2.43% | 1.14% | 1.14% | 1.31% | 0.91% |
Maravai LifeSciences's average Quarter net income forecast for Mar 23 is $56.83M, with a range of $45.47M to $68.20M. MRVI's average Quarter net income forecast represents a -35.00% decrease compared to the company's last Quarter net income of $87.43M (Dec 22).
Maravai LifeSciences SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 4 | 5 | 4 | 5 | 2 | 7 | 9 | 4 | 3 | 3 | 6 | 10 | 9 | 9 | 8 | 8 | 8 | 8 | 9 | 9 | 9 | 9 | 9 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | - | $38.86M | $35.38M | $38.67M | $37.20M | $30.80M | $28.06M | $33.20M | $25.58M | $25.19M | $24.09M | $23.24M | $41.62M |
| Avg Forecast | $20.51M | $20.02M | $18.43M | $16.84M | $20.09M | $19.89M | $19.73M | $18.98M | $16.60M | $19.79M | $21.07M | $31.04M | $18.86M | $22.12M | $20.83M | $28.22M | $22.96M | $53.54M | $64.00M | $25.65M | $57.10M | $55.29M | $53.46M | $17.70M | $24.59M |
| High Forecast | $22.19M | $21.65M | $19.93M | $18.22M | $21.73M | $21.51M | $21.34M | $20.31M | $17.47M | $19.82M | $21.12M | $37.25M | $19.64M | $23.31M | $22.53M | $33.86M | $27.55M | $53.54M | $64.00M | $30.79M | $57.10M | $55.29M | $53.46M | $21.25M | $24.59M |
| Low Forecast | $17.82M | $17.39M | $16.00M | $14.63M | $17.45M | $17.27M | $17.14M | $16.33M | $15.33M | $19.77M | $21.03M | $24.83M | $17.37M | $21.11M | $18.09M | $22.58M | $18.36M | $53.54M | $64.00M | $20.52M | $57.10M | $55.29M | $53.46M | $14.16M | $24.59M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.76% | 1.70% | 1.37% | 1.62% | 0.58% | 0.44% | 1.29% | 0.45% | 0.46% | 0.45% | 1.31% | 1.69% |
Maravai LifeSciences's average Quarter SG&A projection for Dec 23 is $18.86M, based on 6 Wall Street analysts, with a range of $17.37M to $19.64M. The forecast indicates a -51.47% fall compared to MRVI last annual SG&A of $38.86M (Sep 23).
Maravai LifeSciences EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 4 | 5 | 4 | 5 | 2 | 7 | 9 | 4 | 3 | 3 | 6 | 10 | 9 | 9 | 8 | 8 | 8 | 8 | 9 | 9 | 9 | 9 | 9 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | $-0.05 | $-0.05 | $-0.01 | $0.66 | $0.76 | $1.19 | $1.12 | $0.97 | $0.46 | $0.44 | $0.24 | $0.32 |
| Avg Forecast | $-0.01 | $-0.02 | $-0.03 | $-0.04 | $-0.01 | $-0.01 | $-0.02 | $-0.02 | $-0.04 | $-0.01 | - | $-0.03 | $-0.01 | $0.01 | $0.01 | $0.03 | $0.34 | $0.33 | $0.45 | $0.44 | $0.38 | $0.35 | $0.32 | $0.21 | $0.11 |
| High Forecast | $-0.01 | $-0.01 | $-0.02 | $-0.03 | $-0.01 | $-0.01 | $-0.01 | $-0.02 | $-0.02 | $-0.01 | - | $-0.02 | $-0.01 | $0.01 | $0.01 | $0.04 | $0.38 | $0.33 | $0.45 | $0.44 | $0.38 | $0.35 | $0.32 | $0.21 | $0.11 |
| Low Forecast | $-0.01 | $-0.02 | $-0.03 | $-0.04 | $-0.01 | $-0.02 | $-0.02 | $-0.02 | $-0.05 | $-0.01 | - | $-0.03 | $-0.01 | $-0.01 | $0.01 | $0.03 | $0.28 | $0.33 | $0.45 | $0.44 | $0.38 | $0.35 | $0.32 | $0.21 | $0.11 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | -8.83% | -3.90% | -0.32% | 1.93% | 2.31% | 2.62% | 2.55% | 2.52% | 1.31% | 1.39% | 1.14% | 3.05% |
According to 9 Wall Street analysts, Maravai LifeSciences's projected average Quarter EPS for Mar 23 is $0.03, with a low estimate of $0.03 and a high estimate of $0.04. This represents a -95.15% decrease compared to MRVI previous annual EPS of $0.66 (Dec 22).
Maravai LifeSciences Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| MRVI | Maravai LifeSciences | $5.81 | $19.00 | 227.02% | Buy |
| LEGN | Legend Biotech | $34.68 | $89.60 | 158.36% | Buy |
| ABUS | Arbutus Biopharma | $3.46 | $8.50 | 145.66% | Buy |
| ALEC | Alector | $1.89 | $4.00 | 111.64% | Buy |
| ARQT | Arcutis Biotherapeutics | $14.86 | $31.00 | 108.61% | Buy |
| APLS | Apellis Pharmaceuticals | $34.53 | $70.80 | 105.04% | Buy |
| RARE | Ultragenyx Pharmaceutical | $44.95 | $90.00 | 100.22% | Buy |
| CYTK | Cytokinetics | $47.78 | $90.00 | 88.36% | Buy |
| IMVT | Immunovant | $27.91 | $51.00 | 82.73% | Buy |
| AKRO | Akero Therapeutics | $30.61 | $50.00 | 63.35% | Buy |
| EWTX | Edgewise Therapeutics | $30.17 | $46.25 | 53.30% | Buy |
| FOLD | Amicus Therapeutics | $9.89 | $15.00 | 51.67% | Buy |
| DNLI | Denali Therapeutics | $23.22 | $35.00 | 50.73% | Buy |
| ASND | Ascendis Pharma | $140.30 | $211.14 | 50.49% | Buy |
| HRMY | Harmony Biosciences | $33.63 | $48.00 | 42.73% | Buy |
| PTGX | Protagonist Therapeutics | $40.69 | $57.33 | 40.89% | Buy |
| INCY | Incyte | $69.40 | $90.11 | 29.84% | Buy |
| ROIV | Roivant Sciences | $12.15 | $15.50 | 27.57% | Buy |
| AGIO | Agios Pharmaceuticals | $41.96 | $53.50 | 27.50% | Buy |
| KRYS | Krystal Biotech | $169.04 | $210.33 | 24.43% | Buy |
| INSM | Insmed | $73.85 | $87.50 | 18.48% | Buy |
| HALO | Halozyme Therapeutics | $48.60 | $52.00 | 7.00% | Buy |
| ARGX | argenx SE | $638.33 | $558.78 | -12.46% | Buy |